Chronic urticaria (CU) is a dermatological condition characterized by recurrent wheals (hives), angioedema (deep tissue swelling), or both, persisting for over 6 weeks. 1 Unlike acute urticaria, which ...

A prominent feature of CSU is its association with angioedema, observed in approximately 40% to 50% of patients with CSU; around 10% of patients primarily experience angioedema as the main symptom.

Share on Facebook. Opens in a new tab or window Share on Bluesky. Opens in a new tab or window Share on X. Opens in a new tab or window Share on LinkedIn. Opens in a new tab or window "Medical ...

Overall, the CUPID-C trial corroborates earlier evidence that dupilumab can meaningfully reduce itch and hives in ...

Your child's doctor can help, but one of the biggest clues is itchiness. Since your baby or toddler won't be able to tell you how they're feeling, you'll need to watch for scratching behavior. It's ...

Please provide your email address to receive an email when new articles are posted on . Barzolvolimab binds receptor tyrosine kinase KIT to inhibit its activity, which mast cells need for survival.

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Barzolvolimab is an anti-KIT monoclonal antibody. 75% of ...

Acute urticaria affects individuals of all ages but the average age at presentation is in the early 20s. 1 Reports indicate a female preponderance for acute urticaria, except in young children; in ...

Sustained off-treatment efficacy despite barzolvolimab clearance and normalization of tryptase, suggesting disease modification in patients ...

Barzolvolimab improved symptoms in chronic spontaneous urticaria, supporting mast cell targeting as a novel treatment strategy. Read more.

No advanced therapies approved to treat ColdU and SD—diseases of misery that dramatically impact all aspects of patient life Barzolvolimab is the only drug in development to demonstrate clinical ...